Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has announced the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient supporting its lead oncology candidate, ONC010. The program, completed in collaboration with Dalton Pharma Services, established a qualified reference standard to support analytical testing, manufacturing consistency, quality control, and future regulatory and clinical activities.
The milestone strengthens the company’s chemistry, manufacturing and controls (“CMC”) framework and follows recent progress in API manufacturing, precursor scale-up, analytical method development, and chiral purity testing. According to the company, the reference standard program supports its broader strategy of advancing ONC010 toward clinical readiness while ongoing analytical development efforts continue across stability testing, impurity profiling, formulation characterization, and quality control systems.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours.
For more details, the full press release is available at https://ibn.fm/EefIN. The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
